News | December 12, 2022
GSK announces new global headquarters in central London
Company to open new headquarters in 2024
Company to open new headquarters in 2024
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister
Strand’s new offering will help people better understand and manage diseases through genomic sequencing
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The company is making its entry into the Hyderabad market through its unique asset-light business model
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Subscribe To Our Newsletter & Stay Updated
